Headlines

Europe to review safety data for Eisai-Biogen Alzheimer's drug

Published by Global Banking & Finance Review

Posted on January 31, 2025

1 min read

· Last updated: January 26, 2026

Add as preferred source on Google
European Commission evaluates safety data for Eisai-Biogen Alzheimer's drug - Global Banking & Finance Review
The image represents the European Commission's assessment of safety data for Leqembi, Eisai and Biogen's Alzheimer's drug. This review is crucial for early Alzheimer's disease patients.
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) - The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday. The safety

European Commission to Assess Safety Data for Leqembi Alzheimer's Drug

(Reuters) - The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's Alzheimer's drug Leqembi, the agency said on Friday.

The safety information to be reviewed was made available after November, when the regulator had recommended approval of the drug for some patients with early Alzheimer's disease.

(Reporting by Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli)

Key Takeaways

  • The European Commission is reviewing Leqembi's safety data.
  • Leqembi is an Alzheimer's drug by Eisai and Biogen.
  • The review follows a prior approval recommendation.
  • Safety data emerged post-November recommendation.
  • The review impacts early Alzheimer's patients.

Frequently Asked Questions

What is the European Commission reviewing?
The European Commission is reviewing safety information on Eisai and Biogen's Alzheimer's drug Leqembi.
When was the safety information made available?
The safety information was made available after November, following the regulator's recommendation for approval of the drug.
Who reported on the safety review?
The article was reported by Bhanvi Satija in Bengaluru.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category